\-\ Texto\\:\\ \ \(0\)\
\-\ renal\\ chromophobe\\ carcinoma\\ eosinophile\\ type\\ that\\ perforates\\ renal\\ capsule\\ and\\ infiltrates\\ perirenal\\ fat\\ tissue\ \(0\)\
\-\ treated\\ with\\ left\\ radical\\ nephrectomy\ \(0\)\
\-\ \\â\\€\\¢\\ scout\\ abdominal\\ scan\\ from\\ a\\ comuter\\ tomography\\ \\ demonstrates\\ a\\ radio\\-opaque\\ lobular\\ mass\\ \\ projected\\ in\\ the\\ left\\ renal\\ fossa\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ mdct\\ shows\\ a\\ heterogeneous\\ mass\\ arising\\ from\\ the\\ left\\ kidney\ \(0\)\
\-\ \\â\\€\\¢\\ there\\ is\\ irregular\\ enhancement\\ after\\ iv\\ contrast\ \(0\)\
\-\ chromophobe\\ renal\\ cell\\ carcinoma\\,\\ eosinophile\\ type\\,\\ that\\ perforates\\ renal\\ capsule\\ and\\ infiltrates\\ perirenal\\ fat\\ tissue\ \(0\)\
\-\ \\â\\€\\¢\\ renal\\ cell\\ carcinoma\ \(1\)\
\-\ \\*\\ oncocytoma\ \(0\)\
\-\ \\â\\€\\¢\\ transitional\\ cell\\ carcinoma\ \(0\)\
\-\ 40\\ y\\.o\\.\\ woman\\ with\\ evolution\\ over\\ one\\ month\\ or\\ lower\\ urinary\\ tract\\ symptoms\\,\\ left\\ renal\\ pain\\,\\ hematuria\\,\\ and\\ no\\ improvement\\ with\\ treatment\\.\ \(1\)\
\-\ renal\\ cell\\ carcinoma\\:\ \(0\)\
\-\ incidence\\ 80\\-90\\%\\ of\\ all\\ renal\\ malignant\\ primaries\\ in\\ adults\\.\ \(0\)\
\-\ arises\\ from\\ proximal\\ tubular\\ cells\\;\\ 30\\%\\ found\\ incidentally\\ with\\ imaging\\.\ \(0\)\
\-\ tumor\\ growth\\ pattern\\:\\ papillary\\ \\(best\\ prognosis\\)\\;\\ trabecular\\/tubular\\/cystic\\/solid\\ \\(poorer\\ prognosis\\)\\.\\ predisposing\\ factors\\:\\ tobacco\\,\\ von\\ hippel\\-lindau\\ disease\\,\\ hemodialysis\\,\\ acquired\\ cystic\\ disease\\ of\\ uremia\\.\ \(0\)\
\-\ the\\ most\\ common\\ sites\\ of\\ metastases\\ are\\ the\\ lung\\ \\(55\\%\\)\\,\\ lymph\\ nodes\\,\\ liver\\,\\ bone\\,\\ adrenals\\,\\ contralateral\\ kidney\\,\\ brain\\,\\ heart\\,\\ spleen\\.\\ it\\?s\\ important\\ to\\ know\\ that\\ 28\\%\\ of\\ patients\\ have\\ clinically\\ apparent\\ multiple\\ distant\\ metastases\\ at\\ presentation\\!\\ \ \(0\)\
\-\ radiology\\ findings\\ in\\ ct\\:\\ mostly\\ hterogeneous\\ enhancement\\ \\(due\\ to\\ cystic\\ areas\\ or\\ necrosis\\)\\,\\ subcapsular\\/perinephric\\ hemorrhage\\.\\ mri\\ best\\ modality\\ to\\ assess\\ stage\\ iii\\+iv\\ disease\\:\\ low\\ to\\ medium\\ signal\\ intensity\\ on\\ t1wi\\;\\ hyperintense\\ areas\\ are\\ usually\\ due\\ to\\ hemorrhage\\.\\ heterogeneous\\ signal\\ intensity\\ on\\ t2wi\\.\ \(0\)\
\-\ staging\\:\ \(0\)\
\-\ \\ \\ \\ \\ i\\:\\ confined\\ to\\ within\\ renal\\ capsule\ \(0\)\
\-\ \\ \\ \\ ii\\:\\ extension\\ into\\ perinephric\\ fat\\ but\\ confined\\ to\\ gerota\\ fascia\ \(0\)\
\-\ \\ \\ iiia\\:\\ extension\\ into\\ renal\\ vein\\ or\\ ivc\ \(0\)\
\-\ \\ iiib\\:\\ positive\\ lymph\\ nodes\ \(0\)\
\-\ \\ iiic\\:\\ extension\\ into\\ renal\\ vein\\ \\+\\ lymph\\ nodes\ \(0\)\
\-\ \\ iva\\:\\ extensio\\ into\\ adjacent\\ organs\\(\\ other\\ than\\ ipsilateral\\ adrenal\\)\ \(0\)\
\-\ \\ ivb\\:\\ distant\\ metastases\ \(0\)\
\-\ treatment\\ and\\ prognosis\\:\\ recurrence\\ in\\ 11\\%\\ after\\ 10\\ years\\.\\ radical\\ nephrectomy\\ has\\ a\\ 2\\-5\\%\\ operative\\ mortality\\.\\ tumor\\ stage\\ and\\ histological\\ grade\\ are\\ the\\ most\\ important\\ prognosticators\\!\ \(0\)\
\-\ chromophobe\\ carcinoma\\ of\\ kidney\\:\ \(0\)\
\-\ a\\ distinct\\ type\\ of\\ renal\\ cell\\ carcinoma\ \(0\)\
\-\ 5\\%\\ all\ \(0\)\
\-\ males\\=\\ females\\ in\\ contradistinction\\ to\\ classic\\ rcc\\ where\\ male\\ 2\\-3\\:1\\ females\ \(0\)\
\-\ unlike\\ other\\ renal\\ cell\\ carcinomas\\ can\\ be\\ hypovascular\\ on\\ imaging\ \(0\)\
\-\ birt\\-hogg\\-dube\\ syndrome\\ a\\ risk\\ factor\\ for\\ chromophobe\\ renal\\ cell\\ carcinoma\\ and\\ these\\ patients\\ need\\ to\\ be\\ screened\ \(0\)\
\-\ can\\ look\\ identical\\ to\\ oncocytoma\\,\\ and\\ in\\ case\\ reports\\ has\\ coexisted\\ with\\ this\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/entrez\\/query\\.fcgi\\?cmd\\=search\\&db\\=pubmed\\&term\\=renal\\+chromophobe\\+carcinoma\\&tool\\=querysuggestion\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ renal\\:\\ 0\\.08654411964465401\ \(0\)\
\-\ chromophobe\\:\\ 0\\.07924061504688988\ \(0\)\
\-\ carcinoma\\:\\ 0\\.04354027271938637\ \(0\)\
\-\ \\:\\:\\ 0\\.04063909450752953\ \(0\)\
\-\ eosinophile\\:\\ 0\\.03962030752344494\ \(0\)\
\-\ cell\\:\\ 0\\.03630940445184361\ \(0\)\
\-\ perforates\\:\\ 0\\.03468272420358826\ \(0\)\
\-\ \\%\\:\\ 0\\.031355611760498996\ \(0\)\
\-\ capsule\\:\\ 0\\.03118559785577577\ \(0\)\
\-\ perirenal\\:\\ 0\\.028843250117609565\ \(0\)\
\-\ prognosis\\:\\ 0\\.027325917904508373\ \(0\)\
\-\ nodes\\:\\ 0\\.02602039123392295\ \(0\)\
\-\ \\!\\:\\ 0\\.025727981890373855\ \(0\)\
\-\ oncocytoma\\:\\ 0\\.02497717701548322\ \(0\)\
\-\ metastases\\:\\ 0\\.02461167943849203\ \(0\)\
\-\ radical\\:\\ 0\\.02404396638726639\ \(0\)\
\-\ infiltrates\\:\\ 0\\.02390566679775289\ \(0\)\
\-\ lymph\\:\\ 0\\.023255342082772898\ \(0\)\
\-\ confined\\:\\ 0\\.023154861922862258\ \(0\)\
\-\ distant\\:\\ 0\\.022412930460572602\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.021776298923210684\ \(0\)\
\-\ females\\:\\ 0\\.021371125453573392\ \(0\)\
\-\ extension\\:\\ 0\\.020564004412460587\ \(0\)\
\-\ kidney\\:\\ 0\\.02029471992168546\ \(0\)\
\-\ \\&\\:\\ 0\\.020234075677357966\ \(0\)\
\-\ comuter\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ trabecular\\/tubular\\/cystic\\/solid\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ hterogeneous\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ subcapsular\\/perinephric\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ iii\\+iv\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ extensio\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ prognosticators\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ males\\=\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ 2\\-3\\:1\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ birt\\-hogg\\-dube\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ coexisted\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ term\\=renal\\+chromophobe\\+carcinoma\\:\\ 0\\.01981015376172247\ \(0\)\
\-\ type\\:\\ 0\\.01941993861806906\ \(0\)\
\-\ into\\:\\ 0\\.018277090947952424\ \(0\)\
\-\ tool\\=querysuggestion\\:\\ 0\\.018252519648104613\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.01760690282692009\ \(0\)\
\-\ fat\\:\\ 0\\.017520757232909887\ \(0\)\
\-\ radio\\-opaque\\:\\ 0\\.01734136210179413\ \(0\)\
\-\ iiic\\:\\ 0\\.01734136210179413\ \(0\)\
\-\ important\\:\\ 0\\.017252964860880557\ \(0\)\
\-\ projected\\:\\ 0\\.01669488553448676\ \(0\)\
\-\ stage\\:\\ 0\\.016382177208666727\ \(0\)\
\-\ primaries\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ poorer\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ uremia\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ adrenals\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ iiia\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ iva\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ ivb\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ cmd\\=search\\:\\ 0\\.0161934393517582\ \(0\)\
\-\ best\\:\\ 0\\.0161580341523064\ \(0\)\
\-\ contradistinction\\:\\ 0\\.015783727988176278\ \(0\)\
\-\ mdct\\:\\ 0\\.015437321966092552\ \(0\)\
\-\ hypovascular\\:\\ 0\\.015437321966092552\ \(0\)\
\-\ iiib\\:\\ 0\\.015137251420868905\ \(0\)\
\-\ screened\\:\\ 0\\.015137251420868905\ \(0\)\
\-\ \\/\\/www\\.ncbi\\.nlm\\.nih\\.gov\\/entrez\\/query\\.fcgi\\:\\ 0\\.015137251420868905\ \(0\)\
\-\ \\?\\:\\ 0\\.014988222474716885\ \(0\)\
\-\ gerota\\:\\ 0\\.014872570441865796\ \(0\)\
\-\ 80\\-90\\:\\ 0\\.014635805238140344\ \(0\)\
\-\ 2\\-5\\:\\ 0\\.014635805238140344\ \(0\)\
\-\ hemodialysis\\:\\ 0\\.014226093874558423\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.014122225423797779\ \(0\)\
\-\ vein\\:\\ 0\\.0138963295371421\ \(0\)\
\-\ intensity\\:\\ 0\\.013881665961255287\ \(0\)\
\-\ db\\=pubmed\\:\\ 0\\.013879687852474697\ \(0\)\
\-\ medium\\:\\ 0\\.013724647691829862\ \(0\)\
\-\ \\;\\:\\ 0\\.013654524865972541\ \(0\)\
\-\ predisposing\\:\\ 0\\.01357961730725105\ \(0\)\
\-\ identical\\:\\ 0\\.013193436954606874\ \(0\)\
\-\ hippel\\-lindau\\:\\ 0\\.013078171124522489\ \(0\)\
\-\ evolution\\:\\ 0\\.012968530306164214\ \(0\)\
\-\ rcc\\:\\ 0\\.012968530306164214\ \(0\)\
\-\ areas\\:\\ 0\\.012922908634813785\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.01278317565921814\ \(0\)\
\-\ know\\:\\ 0\\.012764099343904156\ \(0\)\
\-\ fascia\\:\\ 0\\.012764099343904156\ \(0\)\
\-\ carcinomas\\:\\ 0\\.012322053738856842\ \(0\)\
\-\ scout\\:\\ 0\\.012167013578212007\ \(0\)\
\-\ perinephric\\:\\ 0\\.012167013578212007\ \(0\)\
\-\ von\\:\\ 0\\.012093328583104163\ \(0\)\
\-\ unlike\\:\\ 0\\.012093328583104163\ \(0\)\
\-\ histological\\:\\ 0\\.011952833398876445\ \(0\)\
\-\ t1wi\\:\\ 0\\.011820607556128281\ \(0\)\
\-\ transitional\\:\\ 0\\.011757302214630087\ \(0\)\
\-\ tobacco\\:\\ 0\\.011577430961431129\ \(0\)\
\-\ arises\\:\\ 0\\.011520537010904634\ \(0\)\
\-\ t2wi\\:\\ 0\\.011520537010904634\ \(0\)\
\-\ distinct\\:\\ 0\\.01141089619254636\ \(0\)\
\-\ mostly\\:\\ 0\\.011206465230286301\ \(0\)\
\-\ cystic\\:\\ 0\\.011077000931468578\ \(0\)\
\-\ staging\\:\\ 0\\.011064490170462633\ \(0\)\
\-\ ipsilateral\\:\\ 0\\.011064490170462633\ \(0\)\
\-\ organs\\:\\ 0\\.011019090828176073\ \(0\)\
\-\ \\,\\:\\ 0\\.010950070065867804\ \(0\)\
\-\ all\\:\\ 0\\.010862577480590071\ \(0\)\
\-\ lobular\\:\\ 0\\.010846144668319605\ \(0\)\
\-\ \\*\\:\\ 0\\.010685562726786696\ \(0\)\
\-\ look\\:\\ 0\\.010685562726786696\ \(0\)\
\-\ contralateral\\:\\ 0\\.010609379464594153\ \(0\)\
\-\ modality\\:\\ 0\\.010535694469486307\ \(0\)\
\-\ sites\\:\\ 0\\.01046434908001534\ \(0\)\
\-\ mortality\\:\\ 0\\.01046434908001534\ \(0\)\
\-\ operative\\:\\ 0\\.010361406302416928\ \(0\)\
\-\ spleen\\:\\ 0\\.01032811397480987\ \(0\)\
\-\ acquired\\:\\ 0\\.010295307683975819\ \(0\)\
\-\ enhancement\\:\\ 0\\.010294331533137241\ \(0\)\
\-\ tomography\\:\\ 0\\.010262973442510426\ \(0\)\
\-\ due\\:\\ 0\\.010248436642484673\ \(0\)\
\-\ ivc\\:\\ 0\\.010231097858258839\ \(0\)\
\-\ signal\\:\\ 0\\.010126176765270917\ \(0\)\
\-\ that\\:\\ 0\\.009950431877924652\ \(0\)\
\-\ patients\\:\\ 0\\.009939661120746185\ \(0\)\
\-\ \\+\\:\\ 0\\.009907413880229764\ \(0\)\
\-\ adults\\:\\ 0\\.009800384556658406\ \(0\)\
\-\ factor\\:\\ 0\\.009800384556658406\ \(0\)\
\-\ papillary\\:\\ 0\\.009748722717951217\ \(0\)\
\-\ adrenal\\:\\ 0\\.009723330458953615\ \(0\)\
\-\ assess\\:\\ 0\\.009624536923175825\ \(0\)\
\-\ to\\:\\ 0\\.009597036144786207\ \(0\)\
\-\ need\\:\\ 0\\.009576722544642603\ \(0\)\
\-\ disease\\:\\ 0\\.009416208143027219\ \(0\)\
\-\ 55\\:\\ 0\\.009309414807875487\ \(0\)\
\-\ hematuria\\:\\ 0\\.009108639301502791\ \(0\)\
\-\ tissue\\:\\ 0\\.00910301657731503\ \(0\)\
\-\ 28\\:\\ 0\\.009051745350976298\ \(0\)\
\-\ imaging\\:\\ 0\\.008998084604294845\ \(0\)\
\-\ improvement\\:\\ 0\\.008960010531829658\ \(0\)\
\-\ tumor\\:\\ 0\\.008953853040947467\ \(0\)\
\-\ tubular\\:\\ 0\\.008942104532618024\ \(0\)\
\-\ urinary\\:\\ 0\\.008889227010347923\ \(0\)\
\-\ most\\:\\ 0\\.00886667479428349\ \(0\)\
\-\ other\\:\\ 0\\.00885230808405595\ \(0\)\
\-\ incidence\\:\\ 0\\.008803772188799072\ \(0\)\
\-\ 11\\:\\ 0\\.008787064371973189\ \(0\)\
\-\ can\\:\\ 0\\.008711111696490201\ \(0\)\
\-\ incidentally\\:\\ 0\\.008705339328892572\ \(0\)\
\-\ factors\\:\\ 0\\.008626482430440278\ \(0\)\
\-\ left\\:\\ 0\\.008594204667621706\ \(0\)\
\-\ from\\:\\ 0\\.008537768852725027\ \(0\)\
\-\ tract\\:\\ 0\\.008505798882188905\ \(0\)\
\-\ apparent\\:\\ 0\\.00849115914955701\ \(0\)\
\-\ clinically\\:\\ 0\\.008419357801677005\ \(0\)\
\-\ recurrence\\:\\ 0\\.00837735300839127\ \(0\)\
\-\ growth\\:\\ 0\\.00834977976661191\ \(0\)\
\-\ ii\\:\\ 0\\.00828229148099646\ \(0\)\
\-\ \\(\\:\\ 0\\.008116423890380454\ \(0\)\
\-\ radiology\\:\\ 0\\.008115756712111693\ \(0\)\
\-\ 40\\:\\ 0\\.0080790170761532\ \(0\)\
\-\ \\)\\:\\ 0\\.008017277439475338\ \(0\)\
\-\ hyperintense\\:\\ 0\\.007972270258209372\ \(0\)\
\-\ arising\\:\\ 0\\.007949221943226925\ \(0\)\
\-\ after\\:\\ 0\\.007946072820715517\ \(0\)\
\-\ i\\:\\ 0\\.00793778583197418\ \(0\)\
\-\ are\\:\\ 0\\.007853082286716417\ \(0\)\
\-\ where\\:\\ 0\\.007837398326240265\ \(0\)\
\-\ fossa\\:\\ 0\\.007826516024047481\ \(0\)\
\-\ treatment\\:\\ 0\\.0077735593689927515\ \(0\)\
\-\ reports\\:\\ 0\\.007741304260311991\ \(0\)\
\-\ cells\\:\\ 0\\.007699880211573028\ \(0\)\
\-\ irregular\\:\\ 0\\.007659205960688494\ \(0\)\
\-\ necrosis\\:\\ 0\\.007580001603246528\ \(0\)\
\-\ 30\\:\\ 0\\.007384470419000169\ \(0\)\
\-\ classic\\:\\ 0\\.007357876132152972\ \(0\)\
\-\ pattern\\:\\ 0\\.007340319863081525\ \(0\)\
\-\ grade\\:\\ 0\\.007314239984159484\ \(0\)\
\-\ http\\:\\ 0\\.00727143505164107\ \(0\)\
\-\ has\\:\\ 0\\.007212134698850688\ \(0\)\
\-\ iv\\:\\ 0\\.0070076964886766156\ \(0\)\
\-\ risk\\:\\ 0\\.006955520555863117\ \(0\)\
\-\ malignant\\:\\ 0\\.006940832980627643\ \(0\)\
\-\ or\\:\\ 0\\.006751838757058703\ \(0\)\
\-\ heart\\:\\ 0\\.006672089098671403\ \(0\)\
\-\ liver\\:\\ 0\\.006620722496253312\ \(0\)\
\-\ presentation\\:\\ 0\\.006614383448294568\ \(0\)\
\-\ 10\\:\\ 0\\.006473312872689686\ \(0\)\
\-\ positive\\:\\ 0\\.006231203573672173\ \(0\)\
\-\ adjacent\\:\\ 0\\.006071542121650039\ \(0\)\
\-\ found\\:\\ 0\\.006051742953824972\ \(0\)\
\-\ be\\:\\ 0\\.005922502127388446\ \(0\)\
\-\ usually\\:\\ 0\\.005831299446891594\ \(0\)\
\-\ brain\\:\\ 0\\.005778318029893848\ \(0\)\
\-\ proximal\\:\\ 0\\.005765265576869697\ \(0\)\
\-\ month\\:\\ 0\\.00576093155236092\ \(0\)\
\-\ treated\\:\\ 0\\.005747979406930021\ \(0\)\
\-\ in\\:\\ 0\\.00568176040638546\ \(0\)\
\-\ years\\:\\ 0\\.005638748622513444\ \(0\)\
\-\ 5\\:\\ 0\\.0056183380279644125\ \(0\)\
\-\ lung\\:\\ 0\\.005562155326379205\ \(0\)\
\-\ y\\.o\\:\\ 0\\.005542425691206068\ \(0\)\
\-\ s\\:\\ 0\\.005507343072167612\ \(0\)\
\-\ syndrome\\:\\ 0\\.0054919248915385206\ \(0\)\
\-\ scan\\:\\ 0\\.0053758909223213\ \(0\)\
\-\ a\\:\\ 0\\.0053474130582283315\ \(0\)\
\-\ mass\\:\\ 0\\.005341397784033999\ \(0\)\
\-\ low\\:\\ 0\\.005339703489587415\ \(0\)\
\-\ shows\\:\\ 0\\.005279491460064897\ \(0\)\
\-\ one\\:\\ 0\\.0052038907490126836\ \(0\)\
\-\ than\\:\\ 0\\.005031570460490503\ \(0\)\
\-\ common\\:\\ 0\\.005025319577430107\ \(0\)\
\-\ these\\:\\ 0\\.0049974038021524505\ \(0\)\
\-\ over\\:\\ 0\\.004889084472224635\ \(0\)\
\-\ on\\:\\ 0\\.0048801641283062564\ \(0\)\
\-\ abdominal\\:\\ 0\\.004799818512633967\ \(0\)\
\-\ symptoms\\:\\ 0\\.004785747139096942\ \(0\)\
\-\ bone\\:\\ 0\\.004771763329123303\ \(0\)\
\-\ woman\\:\\ 0\\.004435736960649228\ \(0\)\
\-\ mri\\:\\ 0\\.004411855853740719\ \(0\)\
\-\ lower\\:\\ 0\\.004318791167109804\ \(0\)\
\-\ it\\:\\ 0\\.004316513223669701\ \(0\)\
\-\ contrast\\:\\ 0\\.004298372329905406\ \(0\)\
\-\ case\\:\\ 0\\.004201133557005103\ \(0\)\
\-\ demonstrates\\:\\ 0\\.004194654385737497\ \(0\)\
\-\ have\\:\\ 0\\.004158287816550768\ \(0\)\
\-\ but\\:\\ 0\\.004095513036030422\ \(0\)\
\-\ findings\\:\\ 0\\.004087274013011145\ \(0\)\
\-\ multiple\\:\\ 0\\.004044507872987121\ \(0\)\
\-\ within\\:\\ 0\\.0036632166480586106\ \(0\)\
\-\ male\\:\\ 0\\.003472371995252749\ \(0\)\
\-\ there\\:\\ 0\\.0028577877673370534\ \(0\)\
\-\ and\\:\\ 0\\.00283160233736074\ \(0\)\
\-\ ct\\:\\ 0\\.0026860756256000965\ \(0\)\
\-\ at\\:\\ 0\\.002601714950183445\ \(0\)\
\-\ pain\\:\\ 0\\.002345186893327494\ \(0\)\
\-\ this\\:\\ 0\\.0021598589063238946\ \(0\)\
\-\ no\\:\\ 0\\.0019335823611321395\ \(0\)\
\-\ for\\:\\ 0\\.001638445277848798\ \(0\)\
\-\ of\\:\\ 0\\.0015708377635683833\ \(0\)\
\-\ the\\:\\ 0\\.0015533627494789416\ \(0\)\
\-\ with\\:\\ 0\\.0013146536639313453\ \(0\)\
\-\ is\\:\\ 0\\.001263574782887024\ \(0\)\
\-\ \\.\\:\\ 0\\.0011168393378940401\ \(0\)\
